Table 2.
Effect | Middle Tertile of HOMA-IR | Highest Tertile of HOMA-IR | ||
---|---|---|---|---|
| ||||
Odds Ratio (95% CI) | P-value | Odds Ratio (95% CI) | P-value | |
|
||||
HIV-infection | 1.49 (1.23–1.81) | <0.001 | 2.46 (1.89–3.21) | <0.001 |
HCV-infection | 1.27 (0.85–1.92) | 0.24 | 2.20 (1.34–3.64) | 0.002 |
Age (per 1 year change) | 1.02 (1.01–1.03) | 0.003 | 1.02 (1.01–1.04) | 0.003 |
Race (Non-Hispanic White vs. Other) | 0.93 (0.75–1.15) | 0.51 | 0.67 (0.50–0.89) | 0.006 |
Current vs. never smoking | 0.96 (0.76–1.22) | 0.75 | 0.95 (0.70–1.30) | 0.76 |
Former vs. never smoking | 0.97 (0.78–1.21) | 0.79 | 0.95 (0.72–1.27) | 0.75 |
BMI (per 1 kg/m2 change) | 1.16 (1.13–1.19) | <0.001 | 1.33 (1.29–1.37) | <0.001 |
Systolic blood pressure (per 10 mmHg) | 1.08 (1.02–1.14) | 0.006 | 1.11 (1.04–1.19) | 0.001 |
Anti-hypertensive use | 1.24 (1.02–1.51) | 0.029 | 1.47 (1.18–1.84) | <0.001 |
Total cholesterol (per 5mg/dL) | 1.01 (1.00–1.02) | 0.047 | 1.01 (1.00–1.02) | 0.14 |
HDL cholesterol (per 5mg/dL) | 0.89 (0.87–0.92) | <0.001 | 0.88 (0.84–0.91) | <0.001 |
Lipid-lowering therapy use | 1.31 (1.08–1.58) | 0.005 | 1.43 (1.14–1.78) | 0.002 |
The highest and middle tertiles are compared to the lowest tertile. Covariates were measured at the time of the HOMA-IR determination.
BMI = Body Mass Index, HCV = Hepatitis C Virus, HIV = Human Immunodeficiency Virus, HDL = High-density lipoprotein